BUSINESS
MC Interview | Dr Reddy's looking to jump ranks in domestic market, eyes M&As in chronic segment
In an exclusive interview with Moneycontrol, Dr Reddy's CFO, M.V. Narasimham highlighted the company's plans on moving up the ranks in the Indian pharma market, areas of inorganic growth opportunities and prospects emerging from the US Biosecure Act.
BUSINESS
Dr Reddy's sets sight on 5th spot in Indian pharma market within 5 years
Dr Reddy's CFO, M,V, Narasimham, highlighted brand planning, collaborations, inorganic growth, and innovation as key drivers for double-digit growth and improved rankings for the drugmaker.
BUSINESS
Apollo Hospitals' well rounded Q2 performance sparks optimism among brokerages
Apollo Hospitals’ strong Q2 earnings, bolstered by growth across its hospital, HealthCo, and lifestyle verticals, drew positive reviews from brokerages. Apollo Hospitals' share price also surged to a record high as brokerages remain bullish over the company's growth prospects across all key segments.
BUSINESS
Apollo Hospitals embarks on mega capex drive, to commission six projects in FY26
Beyond the six projects slated for commissioning in FY26, Apollo Hospitals has four major projects in the pipeline, scheduled to be launched in the next three to four years.
BUSINESS
Wockhardt stock tanks 4.5% as firm launches QIP at sharp discount
The QIP is expected to dilute 5.57 percent of Wockhardt’s post-issue equity capital. The raised funds will strengthen the company’s capital structure, supporting growth or reducing liabilities.
BUSINESS
Apollo Hospitals shares soar to record high after stellar Q2 earnings show
Apollo Hospitals share price surged after the company's earnings topped estimates in Q2, delivering better-than-expected results across key parameters of profit, revenue, and profitability, driven by mid-teens growth across all segments.
BUSINESS
Lack of strong launch pipeline keep brokerages neutral over Dr Reddy's Labs
Even though Dr Reddy's showcased decent earnings performance after adjusting for one-offs in Q2, the absence of a strong launch pipeline keep brokerages cautious over its growth outlook.
BUSINESS
Dr Reddy's R&D expenses to stay around 8.5% in FY25, to launch key biosimilar in 2027
Dr Reddy's ramps up R&D investment with a focus on biosimilars, generics, and biologics, while expecting continued gains from Revlimid amid robust quarterly revenue growth.
BUSINESS
Short Call | Market revival or red ink repeat? The event-packed week may hold the answer; Amara Raja, Azad Engg in focus
The world changes. This is the biggest problem in markets. - Bill Miller
BUSINESS
Apollo Hospitals Q2 Preview: Improved ARPOBs, reduced 24/7 losses to aid strong growth
While earnings forecasts for Apollo Hospitals varies across a vast range of 33 percent, a common thread tying all brokerage expectations is that of the company delivering robust net profit growth in the September quarter.
BUSINESS
Goa unit clearance brings cheer for Cipla, lifts earnings visibility
The clearance of Cipla's Goa facility opens the doors for the launch of Abraxane, which could be a around $120 million opportunity at peak.
BUSINESS
Sun Pharma shares slump 5% after US court ruling stalls Leqselvi launch
In the worst-case scenario, an unfavourable judgment would prevent Sun Pharma from launching Leqselvi until the patent expires, delaying its market entry.
BUSINESS
Dr Reddy's Labs Q2 Preview: Margin pressures to squeeze profit despite steady US sales
Steady US sales may provide some support, but rising R&D costs and operational expenses are expected to weigh on Dr Reddy’s margins, likely impacting net profit in Q2.
BUSINESS
Biocon shares slump 5.5% as net profit takes a dive in Q2
While Biocon reported a dismal earnings show for Q2, the management as well as brokerage remain hopeful for a better second half of FY25. Key triggers for the stock include clarity over USFDA compliance of Biocon's Malaysia and Bengaluru facilities.
BUSINESS
Cipla stock soars 10% after USFDA tags Goa unit as VAI, opens door for Abraxane drug launch
The long haul of regulatory issues at Cipla's Goa manufacturing site had resulted in multiple delays for Abraxane's anticipated launch, prompting analysts to project it as a potential opportunity only in FY27.
BUSINESS
Multiple near-term challenges may hijack Cipla's growth trajectory
Cipla projects a mid-FY26 launch for Advair, while the release of Abraxane is contingent on regulatory clearance of the company's Goa facility. Respiratory drug Albuterol faces intensifying competition, while similar concerns loom over the blockbuster cancer drug Revlimid, whose patent is set to expire in 2026.
BUSINESS
Cipla's major drug launches hit new delays as regulatory hurdles persist
Cipla anticipates a mid-FY26 launch for Advair, while Abraxane’s release hinges on regulatory approval for the drugmaker's Goa facility, slated as the drug’s manufacturing site.
BUSINESS
As Samvat 2081 kicks off, discover the sectors that remain undervalued
As we wave goodbye to Samvat 2080's bull run, Samvat 2081 brings a slow-down-- presenting the perfect opportunity for investors to snag these undervalued gems in the market as banks and autos wave their 'buy me' signals.
BUSINESS
Short Call | An overall slowdown for pharma or just pockets of distress? TVS Motor, HUL, SBI Life in focus
Sound common stocks, bought at sound prices, are always good investments. - Benjamin Graham
BUSINESS
Cipla Q2 Preview: Lack of major US drug launches, high base to keep earnings growth tepid
After a stellar FY24, earnings growth for Cipla is expected to moderate as the launch of major high-margin drugs in the US generics market loses steam amid regulatory hurdles.
BUSINESS
Sun Pharma Q2 Preview: Favourable seasonality, robust specialty sales to keep earnings in the pink of health
India's largest drugmaker--Sun Pharma is expected to deliver one of the strongest earnings growth among peers in Q2, aided by double-digit growth in specialty sales, outperformance in the Indian pharma market and increased Revlimid contribution.
BUSINESS
Goldman Sachs tactically downgrades Indian equities to 'neutral', lowers Nifty 12-month target to 27,000
Goldman Sachs predicts the Nifty will dip about a percent to around 24,500 in the next three months, but anticipates a rebound, rising 3 percent to 25,500 over the following six months.
BUSINESS
Infosys stock slips 4% after slight miss in Q2 earnings
Infosys reported a slight miss on its Q2 net profit and revenue, yet it still raised its FY25 revenue growth guidance, a decision that ignited optimism among brokerages.
BUSINESS
Brokerages cheer as Infosys raises guidance for yet another quarter
Infosys raised its FY25 revenue guidance to 3.75-4.5% in constant currency terms, an increase from the 3-4% range guided in the previous quarter.
